Pharmaceuticals APAC News & Press Release Distribution

Pharmaceuticals

All
Global

CStone announces phase 2 GEMSTONE-201 trial met primary endpoint of objective response rate (ORR) in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL)

* Sugemalimab has the potential to become the world's first immunotherapy to be approved for patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) * The National Medical Products Administration (NMPA) of China has granted the Breakthrough Therapy Designati...

2022-01-13 08:05 5728

Seegene Unveils Blueprint for the Future of Molecular Diagnostics, Including Open Development Platform at the 40th Annual J.P. Morgan Healthcare Conference

SEOUL, South Korea, Jan. 13, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics (MDx) company, today, unveiled its blueprint for the future during a presentation at the 40th annual J.P. Morgan Healthcare virtual Conference. Dr.Jong-Yoon Chun, CEO of Seegene...

2022-01-13 04:00 2592

South Korea Ministry of Food and Drug Safety Approves Novavax COVID-19 Vaccine

GAITHERSBURG, Md., Jan. 12, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, Co. Limited, a vaccine business subsidiary of Korea-based SK Group, today...

2022-01-12 20:43 1859

PostEra Closes $24M in New Financing to Advance Drug Discovery

BOSTON, Jan. 11, 2022 /PRNewswire/ -- PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced $24M in equity financing to accelerate medicinal chemistry and bring new cures to patients. PostEra will use the proceeds to advance a series of ...

2022-01-11 22:00 2229

Cambrex Celebrates its 40th Anniversary while Investing over $100 million in New Drug Substance Manufacturing Capacity

EAST RUTHERFORD, N.J., Jan. 11, 2022 /PRNewswire/ -- Cambrex recently celebrated the 40th anniversary of its founding in 1981. Following forty years of growth and transformation into a leading global contract development and manufacturing organization (CDMO), Cambrex continues its commitment to ...

2022-01-11 21:30 1696

Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets

SHANGHAI and NEW YORK, Jan. 11, 2022 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK), a leading innovation-driven international healthcare group inChina and Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)...

2022-01-11 16:30 2661

Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets

Latest Study Shows Encouraging Results of CanSinoBIO's Inhaled COVID-19 Vaccine as Heterologous Booster

TIANJIN, China, Jan. 11, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced thatPreprints with The Lancet, a collaboration between the research sharing platform SSRN and The Lancet, published a clinical study on the safety and immunogenicity of ...

2022-01-11 15:15 2097

SNIPR BIOME Announces FDA Clearance of Investigational New Drug (IND) Application for SNIPR001, a Novel CRISPR Therapy Targeting Life-Threatening E. coli Infections

COPENHAGEN, Denmark, Jan. 11, 2022 /PRNewswire/ -- SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, is pleased to announce that the US Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) Application, for our first development candidate, enabli...

2022-01-11 14:29 1241

Pfizer Drives Cultural Change in Sustainable and Accessible Data with MicroStrategy

SINGAPORE, Jan. 11, 2022 /PRNewswire/ -- MicroStrategy , the US-based enterprise analytics platform, supportedPfizer, an American multinational pharmaceutical and biotechnology corporation, to usher in a future of sustainable data culture. With the help of solut...

2022-01-11 09:30 2092

Keep Your Home Safe and Build a Protected Community Against Omicron with Circle HealthPod

* Circle HealthPod detects >99.9% of known COVID-19 strains, including the Omicron variant, in approximately 20 minutes * With technology developed at the University of Oxford, the Circle HealthPod is a CE-IVD marked rapid detection system with 98.4% molecular accuracy * Frequent testing wit...

2022-01-11 09:00 2088

Keep Your Home Safe and Build a Protected Community Against Omicron with Circle HealthPod

Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of ASC42, An In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication

HANGZHOU, China and SHAOXING, China, Jan. 11, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces the dosing of the first patient in the Phase II clinical trial of ASC42 for chronic hepatitis B (CHB) indication. The Phase II clinical trial (ClinicalTrials.gov Identifier: NCT051...

2022-01-11 08:30 2510

Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct

SEATTLE, SAN FRANCISCO, SAN JOSE, Calif., NANJING, China, SUZHOU, China and SHANGHAI, Jan. 11, 2022 /PRNewswire/ -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, IASO Biotherapeutics ("IASO Bio"), a clinical-stage biopharmace...

2022-01-11 05:30 3197

Everest Medicines Will Participate in a Clinical Trial with Gilead and MSD to Evaluate Trodelvy® in Combination with KEYTRUDA® (pembrolizumab) in First-Line Metastatic Non-Small Cell Lung Cancer

SHANGHAI, Jan. 10, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), today announced it will participate in a study pursuant to a clinical trial collaboration between Gilead and MSD (Merck & Co., Inc., Kenilworth, N...

2022-01-10 21:35 3013

Clarivate Identifies Seven Potential Blockbuster Drugs in Annual Drugs to Watch Report

Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma Report also examines key therapeutic development areas to watch including mRNA, CRISPR, AI-driven drug discovery and more LONDON, Jan. 10, 2022 /...

2022-01-10 16:00 2510

Insilico Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference

HONG KONG and NEW YORK, Jan. 7, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, will virtually participate in the 40th Annual J.P. Morgan Healthcare Conference.Alex Zhavoronkov, Founder and Chief Executive Officer of I...

2022-01-07 03:55 2117

DiscGenics to Present at 40th Annual J.P. Morgan Healthcare Conference

SALT LAKE CITY, Jan. 6, 2022 /PRNewswire/ -- DiscGenics, Inc., a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that Chie...

2022-01-06 09:05 2279

IND Approved for Pivotal Clinical Study of HER2 Bispecific Antibody KN026 Combined with Chemotherapy in Gastric Cancer

SUZHOU, China, Jan. 5, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced that the IND application for the pivotal clinical trial (KN026-CSP-001) of the anti-HER2 bispecific antibody KN026 combined with che...

2022-01-05 11:49 4225

SI GROUP APPOINTS RUSTOM JILLA AS NEW CHIEF FINANCIAL OFFICER

Jilla brings nearly 20 years of international CFO experience including transformational change SCHENECTADY, N.Y., Jan. 5, 2022 /PRNewswire/ -- SI Group, a leading performance additives company, announced today the appointment ofRustom Jilla as its Senior Vice President and Chief Financial Office...

2022-01-05 02:00 2477

CAI Announces CEO Succession

INDIANAPOLIS, Jan. 4, 2022 /PRNewswire/ -- CAI, a global consulting company that provides technical, operational consulting, and project management services to life sciences, data centers, and industrial process manufacturing industries, today announcedMichael Martin, CAI President, will succeed ...

2022-01-04 22:33 2333

Alamar Biosciences partners with Abcam to drive understanding of the human proteome

FREMONT, Calif. and CAMBRIDGE, England, Jan. 4, 2022 /PRNewswire/ -- Alamar Biosciences (Alamar), a platform company focused on transforming the field of proteomics to enable the early detection of cancer and other diseases, and Abcam (AIM: ABC...

2022-01-04 17:00 1853

1 ... 90 91 929394 95 96 ... 181